TScan Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über TScan Therapeutics Inc Unternehmen

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

TScan Therapeutics Inc Informationen



BörsenkürzelTCRX

Name des UnternehmensTScan Therapeutics Inc

IPO-datumJul 16, 2021

CEOMr. Gavin Macbeath, Ph.D.

Anzahl der mitarbeiter194

WertpapierartOrdinary Share

GeschäftsjahresendeJul 16

Addresse830 Winter Street

StadtWALTHAM

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl02451

Telefon18573999500

Websitehttps://www.tscan.com

BörsenkürzelTCRX

IPO-datumJul 16, 2021

CEOMr. Gavin Macbeath, Ph.D.

Führungskräfte von TScan Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Zoran Zdraveski, J.D., Ph.D.

Chief Legal and Strategy Officer, Secretary

84.61K

+1694.13%

Mr. Gavin Macbeath, Ph.D.

Chief Executive Officer, Director

49.77K

--

Mr. Garry A. Nicholson

Independent Director

--

Mr. R. Keith Woods

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Non-Executive Chairman of the Board

--

Jason A. Amello ,

Chief Financial Officer, Treasurer

--

Dr. Chrystal U. Louis

Chief Medical Officer

--

Ms. Katina Dorton

Independent Director

--

Dr. Barbara J. Klencke, M.D.

Independent Director

--

Dr. Gabriela Gruia, M.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Zoran Zdraveski, J.D., Ph.D.

Chief Legal and Strategy Officer, Secretary

84.61K

+1694.13%

Mr. Gavin Macbeath, Ph.D.

Chief Executive Officer, Director

49.77K

--

Mr. Garry A. Nicholson

Independent Director

--

Mr. R. Keith Woods

Independent Director

--

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Non-Executive Chairman of the Board

--

Jason A. Amello ,

Chief Financial Officer, Treasurer

--

Umsatzaufteilung

FY2025Q2

FY2025Q1

FY2024

FY2023

FY2022

FY2021

Keine Daten

Nach RegionUSD

Name

Umsatz

Anteil

United States

3.08M

0.00%

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Thu, Oct 2

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Lynx1 Capital Advisors LLC

14.97%

BVF Partners L.P.

9.96%

K2 HealthVentures LLC

6.87%

Baker Bros. Advisors LP

5.31%

The Vanguard Group, Inc.

4.10%

Andere

58.80%

Aktionäre

Anteil

Lynx1 Capital Advisors LLC

14.97%

BVF Partners L.P.

9.96%

K2 HealthVentures LLC

6.87%

Baker Bros. Advisors LP

5.31%

The Vanguard Group, Inc.

4.10%

Andere

58.80%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

27.15%

Hedge Fund

21.45%

Venture Capital

15.27%

Investment Advisor/Hedge Fund

7.33%

Research Firm

3.61%

Individual Investor

0.39%

Bank and Trust

0.27%

Andere

24.53%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

198

41.48M

79.05%

-8.70M

2025Q2

192

48.33M

92.38%

-952.90K

2025Q1

198

46.53M

88.95%

-3.07M

2024Q4

184

47.92M

91.75%

+202.11K

2024Q3

172

45.30M

92.65%

-3.14M

2024Q2

147

48.79M

100.07%

+12.56M

2024Q1

110

39.09M

88.67%

+3.45M

2023Q4

95

36.63M

84.04%

+3.23M

2023Q3

84

33.69M

84.61%

-2.13M

2023Q2

78

32.77M

82.58%

-787.78K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Lynx1 Capital Advisors LLC

7.86M

14.97%

-88.79K

-1.12%

Jun 30, 2025

BVF Partners L.P.

5.23M

9.96%

+336.60K

+6.88%

Jun 30, 2025

K2 HealthVentures LLC

3.60M

6.87%

+2.90M

+414.67%

Dec 31, 2024

Baker Bros. Advisors LP

2.78M

5.31%

--

Jun 30, 2025

The Vanguard Group, Inc.

2.15M

4.1%

-207.37K

-8.80%

Jun 30, 2025

Propel Bio Management, LLC

2.09M

3.98%

--

Jun 30, 2025

BlackRock Financial Management, Inc.

1.32M

2.51%

-529.55K

-28.71%

Jun 30, 2025

Bessemer Venture Partners

1.25M

2.37%

--

Jun 30, 2025

Alphabet, Inc.

1.08M

2.05%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

915.95K

1.75%

-1.69M

-64.89%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: 3 hours ago

Name

Anteil

Simplify Propel Opportunities ETF

2.49%

iShares Health Innovation Active ETF

0.1%

iShares Micro-Cap ETF

0.02%

iShares Biotechnology ETF

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

Invesco Dorsey Wright SmallCap Momentum ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

DFA Dimensional US Core Equity Market ETF

0%

iShares Russell 3000 ETF

0%

Simplify Propel Opportunities ETF

Anteil2.49%

iShares Health Innovation Active ETF

Anteil0.1%

iShares Micro-Cap ETF

Anteil0.02%

iShares Biotechnology ETF

Anteil0.01%

Invesco Nasdaq Biotechnology ETF

Anteil0.01%

ProShares Ultra Nasdaq Biotechnology

Anteil0.01%

Invesco Dorsey Wright SmallCap Momentum ETF

Anteil0%

DFA Dimensional US Sustainability Core 1 ETF

Anteil0%

DFA Dimensional US Core Equity Market ETF

Anteil0%

iShares Russell 3000 ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten